Investor Overview Press Releases November 7, 2019 Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs October 31, 2019 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 October 24, 2019 Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1) View all » Events Nov 7, 20195:00 PM EST Q3 2019 Aclaris Therapeutics Inc. Earnings Conference Call Oct 24, 20194:30 PM EDT Aclaris Therapeutics Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-1) Sep 27, 20198:00 am EDT Aclaris Therapeutics R&D Day View all » Feature presentation More presentations coming soon.
November 7, 2019 Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
October 31, 2019 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
October 24, 2019 Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
Oct 24, 20194:30 PM EDT Aclaris Therapeutics Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-1)
